Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Trisomy 21 on post pull-through enterocolitis and bowel function in children with Hirschsprung disease: A PCPLC analysis.

Journal of pediatric surgery·2026
Same author

Report of pediatric colorectal and pelvic reconstruction conference.

Journal of pediatric surgery·2026
Same author

Implementation and Effectiveness of an Enhanced Recovery Protocol for Children Undergoing Surgery: The ENRICH-US Stepped-Wedge Cluster-Randomized Trial.

JAMA surgery·2026
Same author

Eosinophilic esophagitis after tracheoesophageal fistula repair.

Journal of pediatric surgery·2026
Same author

Predictors of successful transitions in a bowel management program.

Journal of pediatric surgery·2026
Same author

Less is more: ECMO utilization and outcomes in congenital diaphragmatic hernia.

Journal of pediatric surgery·2025

Related Experiment Video

Updated: May 18, 2026

Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5
05:45

Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5

Published on: April 26, 2019

Hirschsprung-associated enterocolitis: prevention and therapy.

Philip K Frykman1, Scott S Short

  • 1Division of Pediatric Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Philip.Frykman@cshs.org

Seminars in Pediatric Surgery
|September 19, 2012
PubMed
Summary

Hirschsprung-associated enterocolitis (HAEC) is a serious complication of Hirschsprung disease. This chapter outlines strategies for HAEC prevention, diagnosis, and management to reduce child morbidity and mortality.

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Tissue Engineering of the Intestine in a Murine Model
08:45

Tissue Engineering of the Intestine in a Murine Model

Published on: December 1, 2012

Related Experiment Videos

Last Updated: May 18, 2026

Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5
05:45

Diagnosis of Hirschsprung's Disease by Immunostaining Rectal Suction Biopsies for Calretinin, S100 Protein and Protein Gene Product 9.5

Published on: April 26, 2019

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Tissue Engineering of the Intestine in a Murine Model
08:45

Tissue Engineering of the Intestine in a Murine Model

Published on: December 1, 2012

Area of Science:

  • Pediatric Surgery
  • Gastroenterology
  • Clinical Management

Background:

  • Hirschsprung-associated enterocolitis (HAEC) is the primary cause of death and illness in children with Hirschsprung disease.
  • Effective management of HAEC is critical for improving patient outcomes.

Purpose of the Study:

  • To detail treatment and prevention strategies for Hirschsprung-associated enterocolitis.
  • To outline diagnostic approaches for HAEC and differential diagnoses.

Main Methods:

  • Review of current therapeutic and prophylactic interventions for HAEC.
  • Discussion of diagnostic criteria and methods to differentiate HAEC from other conditions.
  • Identification of high-risk patient populations for targeted prevention.

Main Results:

  • Prevention strategies include managing complications like strictures and employing prophylactic rectal washouts.
  • Early and accurate diagnosis of HAEC is essential for timely intervention.
  • Identifying high-risk individuals allows for proactive management.

Conclusions:

  • Comprehensive management, including prevention, diagnosis, and treatment, is vital for reducing HAEC-related morbidity and mortality.
  • Prophylactic measures and early detection significantly improve outcomes for children with Hirschsprung disease.